Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Retained Earnings (2021 - 2025)

Indivior Pharmaceuticals (INDV) has 4 years of Retained Earnings data on record, last reported at -$35.0 million in Q1 2025.

  • For Q1 2025, Retained Earnings changed N/A year-over-year to -$35.0 million; the TTM value through Mar 2025 reached -$35.0 million, changed N/A, while the annual FY2024 figure was -$36.0 million, 87.5% up from the prior year.
  • Retained Earnings reached -$35.0 million in Q1 2025 per INDV's latest filing, up from -$36.0 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $1.3 billion in Q4 2022 and bottomed at -$288.0 million in Q4 2023.
  • Average Retained Earnings over 4 years is $236.0 million, with a median of -$35.5 million recorded in 2024.
  • Peak YoY movement for Retained Earnings: plummeted 122.1% in 2023, then surged 87.5% in 2024.
  • A 4-year view of Retained Earnings shows it stood at $1.3 billion in 2022, then tumbled by 122.1% to -$288.0 million in 2023, then soared by 87.5% to -$36.0 million in 2024, then rose by 2.78% to -$35.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$35.0 million in Q1 2025, -$36.0 million in Q4 2024, and -$288.0 million in Q4 2023.